Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic

Table 2 Regression analyses comparing biomarkers between all disease groups classified according to pre-lumbar puncture diagnosis, with and without healthy controls

	Global test* including HC (p value)	Global test** excluding HC (p value)	Adjusted*** global test excluding HC (p value)
Aβ1–42	< 0.0001	< 0.0001	< 0.0001
T-tau	< 0.0001	< 0.0001	< 0.0001
T-tau/Aβ1–42 ratio	< 0.0001	< 0.0001	< 0.0001
P-tau-181	< 0.0001	< 0.0001	< 0.0001
NFL	< 0.0001	< 0.0001	< 0.0001
YKL-40	0.0038	0.51	0.04
AβX-38	< 0.0001	0.43	0.17
AβX-40	< 0.0001	0.57	0.30
AβX-42	< 0.0001	0.0001	0.0002
AβX-42/X-40 ratio	< 0.0001	< 0.0001	< 0.0001
APPα	< 0.0001	< 0.0001	0.0001
APPβ	< 0.0001	0.0001	0.0001

Biomarker data are log transformed to achieve normal distribution
Aβ amyloid beta, APP amyloid precursor protein, HC healthy controls, NFL neurofilament light chain, P-tau phosphorylated tau, T-tau total tau
*p < 0.05 provides evidence that the disease groups, including the HC group, do not all have the same mean biomarker value
**As for *, excluding control group
***As for **, also adjusting for age, sex, and time from symptom onset to lumbar puncture

ISSN: 1758-9193